BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

736 related articles for article (PubMed ID: 28202353)

  • 1. The potential clinical promise of 'multimodality' metronomic chemotherapy revealed by preclinical studies of metastatic disease.
    Kerbel RS; Shaked Y
    Cancer Lett; 2017 Aug; 400():293-304. PubMed ID: 28202353
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Decade of Experience in Developing Preclinical Models of Advanced- or Early-Stage Spontaneous Metastasis to Study Antiangiogenic Drugs, Metronomic Chemotherapy, and the Tumor Microenvironment.
    Kerbel RS
    Cancer J; 2015; 21(4):274-83. PubMed ID: 26222079
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Preclinical recapitulation of antiangiogenic drug clinical efficacies using models of early or late stage breast cancer metastatis.
    Kerbel RS; Guerin E; Francia G; Xu P; Lee CR; Ebos JM; Man S
    Breast; 2013 Aug; 22 Suppl 2():S57-65. PubMed ID: 24074794
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Potent efficacy of metronomic topotecan and pazopanib combination therapy in preclinical models of primary or late stage metastatic triple-negative breast cancer.
    Di Desidero T; Xu P; Man S; Bocci G; Kerbel RS
    Oncotarget; 2015 Dec; 6(40):42396-410. PubMed ID: 26623560
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Metronomic chemotherapy in combination with antiangiogenic treatment induces mosaic vascular reduction and tumor growth inhibition in hepatocellular carcinoma xenografts.
    Zhou F; Hu J; Shao JH; Zou SB; Shen SL; Luo ZQ
    J Cancer Res Clin Oncol; 2012 Nov; 138(11):1879-90. PubMed ID: 22736027
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A multitargeted, metronomic, and maximum-tolerated dose "chemo-switch" regimen is antiangiogenic, producing objective responses and survival benefit in a mouse model of cancer.
    Pietras K; Hanahan D
    J Clin Oncol; 2005 Feb; 23(5):939-52. PubMed ID: 15557593
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Metronomic chemotherapy enhances the efficacy of antivascular therapy in ovarian cancer.
    Kamat AA; Kim TJ; Landen CN; Lu C; Han LY; Lin YG; Merritt WM; Thaker PH; Gershenson DM; Bischoff FZ; Heymach JV; Jaffe RB; Coleman RL; Sood AK
    Cancer Res; 2007 Jan; 67(1):281-8. PubMed ID: 17210709
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Postsurgical adjuvant or metastatic renal cell carcinoma therapy models reveal potent antitumor activity of metronomic oral topotecan with pazopanib.
    Jedeszko C; Paez-Ribes M; Di Desidero T; Man S; Lee CR; Xu P; Bjarnason GA; Bocci G; Kerbel RS
    Sci Transl Med; 2015 Apr; 7(282):282ra50. PubMed ID: 25855496
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Highly efficacious nontoxic preclinical treatment for advanced metastatic breast cancer using combination oral UFT-cyclophosphamide metronomic chemotherapy.
    Munoz R; Man S; Shaked Y; Lee CR; Wong J; Francia G; Kerbel RS
    Cancer Res; 2006 Apr; 66(7):3386-91. PubMed ID: 16585158
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anti-angiogenic treatment of breast cancer using metronomic low-dose chemotherapy.
    Munoz R; Shaked Y; Bertolini F; Emmenegger U; Man S; Kerbel RS
    Breast; 2005 Dec; 14(6):466-79. PubMed ID: 16199161
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Postsurgical adjuvant tumor therapy by combining anti-angiopoietin-2 and metronomic chemotherapy limits metastatic growth.
    Srivastava K; Hu J; Korn C; Savant S; Teichert M; Kapel SS; Jugold M; Besemfelder E; Thomas M; Pasparakis M; Augustin HG
    Cancer Cell; 2014 Dec; 26(6):880-895. PubMed ID: 25490450
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Metronomic chemotherapy for advanced breast cancer patients.
    Cazzaniga ME; Dionisio MR; Riva F
    Cancer Lett; 2017 Aug; 400():252-258. PubMed ID: 28017894
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Analysis of acquired resistance to metronomic oral topotecan chemotherapy plus pazopanib after prolonged preclinical potent responsiveness in advanced ovarian cancer.
    Cruz-Muñoz W; Di Desidero T; Man S; Xu P; Jaramillo ML; Hashimoto K; Collins C; Banville M; O'Connor-McCourt MD; Kerbel RS
    Angiogenesis; 2014 Jul; 17(3):661-73. PubMed ID: 24569856
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antitumor effects in mice of low-dose (metronomic) cyclophosphamide administered continuously through the drinking water.
    Man S; Bocci G; Francia G; Green SK; Jothy S; Hanahan D; Bohlen P; Hicklin DJ; Bergers G; Kerbel RS
    Cancer Res; 2002 May; 62(10):2731-5. PubMed ID: 12019144
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Metronomic chemotherapy and immunotherapy in cancer treatment.
    Chen YL; Chang MC; Cheng WF
    Cancer Lett; 2017 Aug; 400():282-292. PubMed ID: 28189534
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intermittent metronomic drug schedule is essential for activating antitumor innate immunity and tumor xenograft regression.
    Chen CS; Doloff JC; Waxman DJ
    Neoplasia; 2014 Jan; 16(1):84-96. PubMed ID: 24563621
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Low-dose metronomic chemotherapy of paclitaxel synergizes with cetuximab to suppress human colon cancer xenografts.
    Zhang M; Tao W; Pan S; Sun X; Jiang H
    Anticancer Drugs; 2009 Jun; 20(5):355-63. PubMed ID: 19318912
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Potent preclinical impact of metronomic low-dose oral topotecan combined with the antiangiogenic drug pazopanib for the treatment of ovarian cancer.
    Hashimoto K; Man S; Xu P; Cruz-Munoz W; Tang T; Kumar R; Kerbel RS
    Mol Cancer Ther; 2010 Apr; 9(4):996-1006. PubMed ID: 20371722
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Metronomic oral topotecan with pazopanib is an active antiangiogenic regimen in mouse models of aggressive pediatric solid tumor.
    Kumar S; Mokhtari RB; Sheikh R; Wu B; Zhang L; Xu P; Man S; Oliveira ID; Yeger H; Kerbel RS; Baruchel S
    Clin Cancer Res; 2011 Sep; 17(17):5656-67. PubMed ID: 21788355
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Metronomic low-dose chemotherapy boosts CD95-dependent antiangiogenic effect of the thrombospondin peptide ABT-510: a complementation antiangiogenic strategy.
    Yap R; Veliceasa D; Emmenegger U; Kerbel RS; McKay LM; Henkin J; Volpert OV
    Clin Cancer Res; 2005 Sep; 11(18):6678-85. PubMed ID: 16166447
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 37.